Get the Stockscreener App
1.49
2.61%
-0.04
Cardiol Therapeutics Inc stock is traded at $1.49, with a volume of 450.88K.
It is down -2.61% in the last 24 hours and up +5.67% over the past month.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
See More
Previous Close:
$1.53
Open:
$1.56
24h Volume:
450.88K
Relative Volume:
1.94
Market Cap:
$123.15M
Revenue:
-
Net Income/Loss:
$-21.65M
P/E Ratio:
-4.4866
EPS:
-0.3321
Net Cash Flow:
$-15.84M
1W Performance:
+6.43%
1M Performance:
+5.67%
6M Performance:
+13.74%
1Y Performance:
-33.78%
1-Day Range:
$1.43
$1.56
1-Week Range:
$1.36
$1.59
52-Week Range:
$0.7709
$2.63
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.49 | 119.02M | 0 | -21.65M | -15.84M | -0.3321 |
|
ZTS
Zoetis Inc
|
150.32 | 67.73B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 45.73B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.775 | 44.38B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.50 | 18.97B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
299.58 | 13.73B | 2.99B | 1.21B | 1.13B | 25.06 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Initiated | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jun-26-24 | Initiated | ROTH MKM | Buy |
| Apr-22-24 | Initiated | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Stock (CRDL) Latest News
Will Cardiol Therapeutics Inc. rebound enough to break evenDay Trading Plan with Entry Risk Management - Newser
What technical models suggest about Cardiol Therapeutics Inc.’s comebackLong-Term Growth Trend Summary With Confidence - Newser
Why Cardiol Therapeutics Inc. stock attracts strong analyst attentionMomentum Prediction Based on AI Backtesting - Newser
Analyzing drawdowns of Cardiol Therapeutics Inc. with statistical tools3-Year Equity Summary With Setup Insights - Newser
What makes Cardiol Therapeutics Inc. stock price move sharplyMulti-Year Investment Performance Summary Report - Newser
Chart based analysis of Cardiol Therapeutics Inc. trendsVolume Confirmed Setup with Entry Confidence - Newser
Visualizing Cardiol Therapeutics Inc. stock with heatmapsAI Powered Stock Market Trend Forecast - Newser
How to integrate Cardiol Therapeutics Inc. into portfolio analysis toolsProfitable Trading Blueprint with Entry Zones - Newser
Real time alert setup for Cardiol Therapeutics Inc. performance Entry Confirmation Based on Volatility Analysis - Newser
How to integrate Cardiol Therapeutics Inc. into portfolio analysis tools Watchlist Generator for Smart Money Signals - Newser
Why is Cardiol Therapeutics Inc. stock attracting strong analyst attentionGame-changing capital returns - jammulinksnews.com
When is Cardiol Therapeutics Inc. stock expected to show significant growthAccelerate your capital gains today - jammulinksnews.com
How does Cardiol Therapeutics Inc. compare to its industry peersDiscover stocks with strong growth potential - jammulinksnews.com
Moving Average Trends for Cardiol Therapeutics Inc. Stock: What They IndicateReal Trader Insights - Newser
Is Cardiol Therapeutics Inc. Stock a Good Fit for Conservative InvestorsHigh Potential Shares - Newser
Published on: 2025-07-27 15:05:27 - jammulinksnews.com
How strong is Cardiol Therapeutics Inc. company’s balance sheetMaximize your portfolio’s earning potential - jammulinksnews.com
What drives Cardiol Therapeutics Inc. stock priceFree Stock Selection - PrintWeekIndia
Does Cardiol Therapeutics Inc. stock pay reliable dividendsSkyrocketing profit margins - jammulinksnews.com
How high can Cardiol Therapeutics Inc. stock price go in 2025Rapidly expanding wealth - jammulinksnews.com
Is Cardiol Therapeutics Inc. stock a good hedge against inflationSuperior risk-adjusted returns - jammulinksnews.com
Where are the Opportunities in (CRDL) (CRDL:CA) - news.stocktradersdaily.com
What analysts say about Cardiol Therapeutics Inc. stockSuperior stock growth - Autocar Professional
Cardiol Therapeutics stock holds Buy rating at H.C. Wainwright after trial update - Investing.com Canada
Cardiol Therapeutics Achieves Database Lock in ARCHER Trial for Acute Myocarditis - MSN
Is Cardiol Therapeutics Inc. a good long term investmentTriple-digit profit margins - jammulinksnews.com
Cardiol rises on database lockup for acute myocarditis therapy trial - Seeking Alpha
Cardiol To Report ARCHER Study Data Within The Next Two Weeks - Nasdaq
Cardiol Therapeutics Announces Database Lock for Phase II ARCHER - GuruFocus
Cardiol Therapeutics announces database lock for myocarditis trial By Investing.com - Investing.com Canada
Cardiol Therapeutics announces database lock for myocarditis trial - Investing.com Australia
Breakthrough Acute Myocarditis Drug Trial Locks Database, Results Due in 2 Weeks - Stock Titan
Cardiol Therapeutics Inc. Stock Analysis and ForecastFastest-growing stock picks - jammulinksnews.com
(CRDL) Technical Pivots with Risk Controls (CRDL:CA) - news.stocktradersdaily.com
Cardiol Therapeutics Inc Stock (CRDL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.06%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):